We have started to test telomerase gene therapy to rejuvenate microglial cells in a Alzheimer’s disease human study, building on promising research study data. There is mounting evidence to indicate that telomerase plays an active role in protection from Tau Pathology. Various experiments have encouraged us to pursue this therapy with the goal of eliminating the suffering this disease brings.
Integrated Health System’s gene therapy targeting neurodegeneration utilizes an adeno-associated virus (AAV) vector platform modified for the enhanced delivery to neural tissue. The genes to treat the disorder are inserted into the delivery method, which then delivers the genes of interest to the patient’s cells. In recent years, AAV gene therapies have been tested in humans with great success, and no evidence of adverse effects has been visible. There are numerous clinical trials currently being conducted with AAV gene therapy for many diseases.
A Research Review: Neurodegeneration and Telomerase
Critically short telomeres lead to oxidative stress and neuroinflammation – established contributors to Alzheimer’s pathology.
The TERT protein appears to reduce toxic tau tangle accumulation and alleviate mitochondrial stress.
Senescent microglial cells are linked to Alzheimer’s. Telomerase activation can prevent cellular senescence by repairing critically short telomeres.
Aggregated amyloid beta and Alzheimer’s pathology inhibit telomerase expression; accelerating disease progression by accelerating microglial senescence.
Immune cell senescence is associated with Alzheimer’s onset.
Astrocyte senescence is also correlated with Alzheimer’s onset and may be prevented by telomerase induction.
Old microglia exposed to the conditioned media of young microglia are better able to reduce amyloid plaque formation.
Meet our doctor: Dr. Jason Williams, MD
Dr Williams CMO is a radiologist. He obtained his medical degree from Louisiana State University and has also completed an internship in Internal Medicine at The University of South Alabama. He is passionate about gene and cellular therapies, administered under image guidance. Image guided cancer therapies are also one of his interests. For several years, he did research with adenoviral vector technology used to treat cancer. He was selected for the RSNA Research Fellow Award. He has completed training in image guided cancer and spine procedures, and is board certified by the American Board of Radiology. He has research interests in gene therapy and stem cell reprogramming, as well as using CT and MRI for minimally invasive procedures related to the spine and cancer.
Our technology and care, your healthy longevity:
IHS, in partnership with BioViva, is dedicated to providing you with the latest breakthroughs in medical technologies to help you at this difficult time in your life. Our doctors are here to help you every step of the way. To schedule your 20 minutes consultation with a doctor from Integrated Health Systems, please click
*Please note that the default length of an appointment is 20 minutes, and the cost is $100 USD. You have an option to schedule more time.
Agostinho, Paula, Rodrigo A Cunha, and Catarina Oliveira. “Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer’s disease.” Current pharmaceutical design 16.25 (2010): 2766-2778
Bhat, Rekha, et al. “Astrocyte senescence as a component of Alzheimer’s disease.” PloS one 7.9 (2012): e45069
Chinta, Shankar J., et al. “Cellular senescence and the aging brain.” Experimental gerontology 68 (2015): 3-7
Daria et al. “Young microglia restore amyloid plaque clearance of aged microglia”. The EMBO Journal. (2016)
Flanary, Barry E., et al. “Evidence that aging and amyloid promote microglial cell senescence.” Rejuvenation research 10.1 (2007): 61-74
Haendeler, Judith, et al. “Mitochondrial telomerase reverse transcriptase binds to and protects mitochondrial DNA and function from damage.” Arteriosclerosis, thrombosis, and vascular biology 29.6 (2009): 929-935
Kronenberg, Golo, et al. “Repression of telomere-associated genes by microglia activation in neuropsychiatric disease.” European Archives of Psychiatry and Clinical Neuroscience (2016): 1-5.
Maccioni, Ricardo B., et al. “The role of neuroimmunomodulation in Alzheimer’s disease.” Annals of the New York Academy of Sciences 1153.1 (2009): 240-246
Mhatre, Molina, Robert A. Floyd, and Kenneth Hensley. “Oxidative stress and neuroinflammation in Alzheimer’s disease and amyotrophic lateral sclerosis: common links and potential therapeutic targets.” Journal of Alzheimer’s disease 6.2 (2004): 147-157
Panossian, L. A., et al. “Telomere shortening in T cells correlates with Alzheimer’s disease status.” Neurobiology of aging 24.1 (2003): 77-84.
Rolyan, Harshvardhan, et al. “Telomere shortening reduces Alzheimer’s disease amyloid pathology in mice.” Brain (2011)
Salminen, Antero, et al. “Astrocytes in the aging brain express characteristics of senescence‐associated secretory phenotype.” European Journal of Neuroscience 34.1 (2011): 3-11
Silva, Patricia Natalia Oliveira, et al. “Promoter methylation analysis of SIRT3, SMARCA5, HTERT and CDH1 genes in aging and Alzheimer’s disease.” Journal of Alzheimer’s Disease 13.2 (2008): 173-176
Spilsbury, Alison, et al. “The role of telomerase protein TERT in Alzheimer’s disease and in tau-related pathology in vitro.” The Journal of Neuroscience 35.4 (2015): 1659-1674
Wang, Jiasi, et al. “New insights in amyloid beta interactions with human telomerase.” Journal of the American Chemical Society 137.3 (2015): 1213-1219
Zhu, Haiyan, Weiming Fu, and Mark P. Mattson. “The Catalytic Subunit of Telomerase Protects Neurons Against Amyloid β‐Peptide‐Induced Apoptosis.” Journal of neurochemistry 75.1 (2000): 117-124
Zhu, Xiongwei, et al. “Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease.” Journal of Neuropathology & Experimental Neurology 59.10 (2000): 880-888